Aurobindo gets FDA nod for eletriptan hydrobromide tablets
EAST WINDSOR, N.J. — Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for eletriptan hydrobromide tablets, 20 mg and 40 mg. Aurobindo’s eletriptan hydrobromide tablets are an AB-rated generic equivalent to the reference listed drug, Pfizer’s RELPAX. Eletriptan hydrobromide is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated
